NCT02964013: Study of MK-7684 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001)

NCT02964013
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
https://ClinicalTrials.gov/show/NCT02964013

Comments are closed.

Up ↑